Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,815
archived clinical trials in
Parkinsons Disease

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
West Bloomfield, MI
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Toms River, NJ
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Toms River, NJ
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Commack, NY
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Commack, NY
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Asheville, NC
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Asheville, NC
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Charlotte, NC
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Durham, NC
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Fargo, ND
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Cleveland, OH
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Medford, OR
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Medford, OR
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Abington, PA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Abington, PA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Providence, RI
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Providence, RI
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Port Royal, SC
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Port Royal, SC
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Houston, TX
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated:  10/26/2012
Clinical Research Facility
mi
from
Henrico, VA
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037 AM3)
A Phase 3, 12 Week, Double Blind, Placebo Controlled Efficacy and Safety Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease. (Phase 3; Protocol No. P07037)
Status: Enrolling
Updated: 10/26/2012
Clinical Research Facility
mi
from
Henrico, VA
Click here to add this to my saved trials
Cognitive Decline in Non-demented PD
Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study
Status: Enrolling
Updated:  11/9/2012
Oregon Health and Science University
mi
from
Portland, OR
Cognitive Decline in Non-demented PD
Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study
Status: Enrolling
Updated: 11/9/2012
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls
Status: Enrolling
Updated:  12/13/2012
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects
Evaluation of [18F] MK-9470 and PET as a Marker of Cannabinoid-1 Receptor Activity in Subjects With Parkinson Disease Compared With Healthy Controls
Status: Enrolling
Updated: 12/13/2012
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Birmingham, AL
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
San Diego, CA
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
New Haven, CT
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Kansas City, KA
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Detroit, MI
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Grand Island, NE
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Grand Island, NE
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Teaneck, NJ
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Teaneck, NJ
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Akron, OH
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated:  12/20/2012
Clinical Research Facility
mi
from
Houston, TX
A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
A Phase IIa, 12 Week, Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease
Status: Enrolling
Updated: 12/20/2012
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Status: Enrolling
Updated:  1/14/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Status: Enrolling
Updated: 1/14/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  1/18/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 1/18/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  1/18/2013
Novartis Investigative Site
mi
from
Chicago, IL
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 1/18/2013
Novartis Investigative Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  1/18/2013
Novartis Investigative Site
mi
from
St Louis, MO
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 1/18/2013
Novartis Investigative Site
mi
from
St Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  1/18/2013
Novartis Investigative Site
mi
from
Mineola, NY
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 1/18/2013
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  1/18/2013
Novartis Investigative Site
mi
from
Cincinatti, OH
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 1/18/2013
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated:  1/18/2013
Novartis Investigative Site
mi
from
Salt Lake City, UT
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Oral Dose Study to Assess the Efficacy, Safety and Tolerability of AQW051 in Reducing L-dopa Induced Dyskinesias in Parkinson's Patients With Moderate to Severe L-dopa Induced Dyskinesias
Status: Enrolling
Updated: 1/18/2013
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Study
Optivise Map Concordance Study
Status: Enrolling
Updated:  3/25/2013
Scripps Clinic, Division of Neurology
mi
from
La Jolla, CA
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Study
Optivise Map Concordance Study
Status: Enrolling
Updated: 3/25/2013
Scripps Clinic, Division of Neurology
mi
from
La Jolla, CA
Click here to add this to my saved trials
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Study
Optivise Map Concordance Study
Status: Enrolling
Updated:  3/25/2013
Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center
mi
from
Kansas City, KA
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Study
Optivise Map Concordance Study
Status: Enrolling
Updated: 3/25/2013
Parkinson's Disease and Movement Disorder Center, University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Optimizing DBS Electrode Placement and Programming
Optimizing DBS Electrode Placement and Programming Using a Combination of High‐Field MRI, Intraoperative Electrophysiology, and Computational Modeling.
Status: Enrolling
Updated:  3/25/2013
Department of Neurosurgery, University of Minnesota
mi
from
Minneapolis, MN
Optimizing DBS Electrode Placement and Programming
Optimizing DBS Electrode Placement and Programming Using a Combination of High‐Field MRI, Intraoperative Electrophysiology, and Computational Modeling.
Status: Enrolling
Updated: 3/25/2013
Department of Neurosurgery, University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Optimizing DBS Electrode Placement and Programming
Optimizing DBS Electrode Placement and Programming Using a Combination of High‐Field MRI, Intraoperative Electrophysiology, and Computational Modeling.
Status: Enrolling
Updated:  3/25/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Optimizing DBS Electrode Placement and Programming
Optimizing DBS Electrode Placement and Programming Using a Combination of High‐Field MRI, Intraoperative Electrophysiology, and Computational Modeling.
Status: Enrolling
Updated: 3/25/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Barrow Neurological Institute
mi
from
Phoenix, AZ
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Barrow Neurological Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
San Francisco Clinical Research Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
The Parkinson's Institute
mi
from
Sunnyvale, CA
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
The Parkinson's Institute
mi
from
Sunnyvale, CA
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
The Institute for Neurodegenerative Disorders
mi
from
New Haven, CT
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Parkinson's Disease and Movement Disorder Center
mi
from
Boca Raton, FL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Parkinson's Disease and Movement Disorder Center
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Neurologic Consultants, PA
mi
from
Fort Lauderdale, FL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Neurologic Consultants, PA
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
University of Florida
mi
from
Gainesville, FL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Parkinson's Disease Treatment Center of SW Florida
mi
from
Port Charlotte, FL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Parkinson's Disease Treatment Center of SW Florida
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
Neurology Clinical Research Inc.
mi
from
Sunrise, FL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
Neurology Clinical Research Inc.
mi
from
Sunrise, FL
Click here to add this to my saved trials
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated:  3/27/2013
University Of South Florida Medical Center
mi
from
Tampa, FL
Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa
A Phase III, Double-blind, Placebo-controlled, Randomised Trial to Determine the Efficacy and Safety of a Dose Range of 50 to 100 mg/Day of Safinamide, as add-on Therapy, in Subjects With Idiopathic Parkinson's Disease With Motor Fluctuations, Treated With a Stable Dose of Levodopa and Who May be Receiving Concomitant Treatment With Stable Doses of a Dopamine Agonist, an Anticholinergic and/or Amantadine
Status: Enrolling
Updated: 3/27/2013
University Of South Florida Medical Center
mi
from
Tampa, FL
Click here to add this to my saved trials